Home
/
Serina Therapeutics, Inc.
/
Financials
/
Quarterly
Serina Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Serina Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 13, 2025
Q2
2025
Jun 30, 2025
$130.0K
Aug 11, 2025
Q1
2025
Mar 31, 2025
$0
May 8, 2025
Q3
2025
Sep 30, 2024
$14.0K
Nov 13, 2025
Q2
2025
Jun 30, 2024
$51.0K
Aug 11, 2025
Q1
2025
Mar 31, 2024
$5.0K
May 8, 2025
Q3
2024
Sep 30, 2023
$29.0K
Nov 12, 2024
Q2
2024
Jun 30, 2023
$7.0K
Aug 9, 2024
Q1
2024
Mar 31, 2023
$30.0K
May 14, 2024
Q3
2023
Sep 30, 2022
$9.0K
Nov 14, 2023
Q2
2023
Jun 30, 2022
$12.0K
Aug 14, 2023
Q1
2023
Mar 31, 2022
$5.0K
May 12, 2023
Q3
2022
Sep 30, 2021
$24.0K
Nov 10, 2022
Q2
2022
Jun 30, 2021
$37.0K
Aug 12, 2022
Q1
2022
Mar 31, 2021
$56.0K
May 13, 2022
Q3
2021
Sep 30, 2020
$69.0K
Nov 12, 2021
Q2
2021
Jun 30, 2020
$45.0K
Aug 13, 2021
Q1
2021
Mar 31, 2020
$89.0K
May 17, 2021
Q3
2020
Sep 30, 2019
$411.0K
Nov 16, 2020
Q2
2020
Jun 30, 2019
$380.0K
Aug 14, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($4.59M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($6.45M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($4.81M)
May 8, 2025
Q3
2025
Sep 30, 2024
$1.41M
Nov 13, 2025
Q2
2025
Jun 30, 2024
$5.20M
Aug 11, 2025
Q1
2025
Mar 31, 2024
($15.02M)
May 8, 2025
Q3
2024
Sep 30, 2023
$1.75M
Nov 12, 2024
Q2
2024
Jun 30, 2023
$808.0K
Aug 9, 2024
Q1
2024
Mar 31, 2023
$1.66M
May 14, 2024
Q3
2023
Sep 30, 2022
($2.44M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($2.62M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($2.71M)
May 12, 2023
Q3
2022
Sep 30, 2021
($1.96M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($2.47M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($2.09M)
May 13, 2022
Q3
2021
Sep 30, 2020
($2.54M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($2.69M)
Aug 13, 2021
Q3
2022
Jun 2, 2020
$2.00M
Nov 10, 2022
Q2
2022
Jun 1, 2020
$2.00M
Aug 12, 2022
Q1
2023
Jun 1, 2020
$2.00M
May 12, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($6.39M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($5.57M)
Aug 11, 2025
Q1
2025
Mar 31, 2025
($5.86M)
May 8, 2025
Q3
2025
Sep 30, 2024
($5.31M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($3.87M)
Aug 11, 2025
Q1
2025
Mar 31, 2024
($2.32M)
May 8, 2025
Q3
2024
Sep 30, 2023
($1.46M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($945.0K)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($962.0K)
May 14, 2024
Q3
2023
Sep 30, 2022
($1.55M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($1.59M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($2.05M)
May 12, 2023
Q3
2022
Sep 30, 2021
($1.67M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($2.21M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($2.19M)
May 13, 2022
Q3
2021
Sep 30, 2020
($2.40M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($2.37M)
Aug 13, 2021
Q1
2021
Mar 31, 2020
($3.01M)
May 17, 2021
Q3
2020
Sep 30, 2019
($3.28M)
Nov 16, 2020
Q2
2020
Jun 30, 2019
($3.44M)
Aug 14, 2020